Dentists in Aberdeen, NC Accepting Medicare
4 Dentists found. Showing 1 - 4
 Amanda Kuhn Grimshaw, DSS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1902 N Sandhills Blvd Ste H, Aberdeen, NC 28315 Phone: 910-692-4450 |
Dr. Christine Pirozzolo Gatti, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 908 N Sandhills Blvd, Aberdeen, NC 28315 Phone: 910-944-5600 Fax: 910-944-9334 |
 David Rittenhouse Kuhn, DMD Dentist - Oral and Maxillofacial Pathology Medicare: Not Enrolled in Medicare Practice Location: 1902 N Sandhills Blvd Ste H, Aberdeen, NC 28315 Phone: 910-692-4450 |
David Rittenhouse Kuhn Jr., DMD Dentist - Oral and Maxillofacial Pathology Medicare: Not Enrolled in Medicare Practice Location: 1902 N Sandhills Blvd Ste H, Aberdeen, NC 28315 Phone: 910-692-4450 |
News Archive
World Bank approves $10 million grant to Rwanda for HIV/AIDS efforts
The World Bank recently approved a $10 million grant for Rwanda to help the country's HIV/AIDS efforts, the New Times/AllAfrica.com reports.
Preteen girls more likely than boys to retaliate
Girls in middle and elementary schools involved in violent incidents may be more likely than boys of the same age to be retaliating for a previous event, to experience the violence at home, and to have a family member intervene.
Natural compound could reduce risk of developing triple-negative breast cancer metastasis
More than 100 women die from breast cancer every day in the United States. Triple-negative breast cancers, which comprise 15 to 20 percent of all breast tumors, are a particularly deadly type of breast disease that often metastasize to distant sites.
Researchers identify two dozen pesticides linked with mammary gland tumors
In an analysis of how regulators review pesticides for their potential to cause cancer, researchers at Silent Spring Institute identified more than two dozen registered pesticides that were linked with mammary gland tumors in animal studies.
FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.
› Verified 3 days ago
Pharmacists
Counselors
Clinical Social Workers
Dentists
Psychologists